CompletedPHASE2, PHASE3NCT00740285

Effectiveness and Safety of Lidocaine for Scleroderma

Studying Limited systemic sclerosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Federal University of São Paulo
Principal Investigator: Rachel Riera, MD
Universidade Federal de São Paulo
Intervention: Lidocaine 2% without vessel constrictor(drug)
Enrollment: 26 enrolled
Eligibility: 18-60 years · All sexes
Timeline: 2004 – 2007

Study locations (1)

Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00740285 on ClinicalTrials.gov

← Back to all trials